10-K: Spero Therapeutics Reports 2025 Net Income, Focuses on Tebipenem HBr

Spero Therapeutics achieved a net income of $8.6 million in 2025, driven by collaboration revenue, as it streamlines its pipeline to focus on the FDA approval process for tebipenem HBr with GSK.

Summary

• Spero Therapeutics reported a net income of $8.6 million for the year ended December 31, 2025, a significant improvement from a net loss of $68.6 million in 2024.
• Total revenues increased to $66.8 million in 2025 from $48.0 million in 2024, primarily due to collaboration revenue from GSK and Pfizer.
• Research and development expenses decreased substantially to $38.5 million in 2025 from $96.8 million in 2024, following the cessation of the SPR206 and SPR720 programs.
• The company has ceased development of its SPR206 program (March 2025) and SPR720 oral program (November 2025), re-prioritizing resources to tebipenem HBr.
• Tebipenem HBr, a potential first oral carbapenem to treat adult patients with complicated urinary tract infections (cUTIs), including pyelonephritis, met its primary endpoint in the pivotal Phase 3 PIVOT-PO trial, which was stopped early for efficacy in May 2025.
• GSK submitted a New Drug Application (NDA) Class 2 resubmission for tebipenem HBr to the FDA in December 2025, which has been accepted, with a Prescription Drug User Fee Act (PDUFA) date set for June 18, 2026.
• Spero received a $25.0 million milestone payment in February 2026 upon GSK's NDA filing for tebipenem HBr.
• The company's cash and cash equivalents were $40.3 million as of December 31, 2025, and are expected to fund operations into 2028.
• An accumulated deficit of $451.1 million was reported as of December 31, 2025.
• The Pfizer License Agreement for SPR206 was mutually terminated on December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the significant financial turnaround to net income, the successful Phase 3 trial results for tebipenem HBr, and the clear regulatory path with a PDUFA date. The resolution of legal and SEC issues, coupled with a focused pipeline, reduces uncertainty, though future funding needs and market acceptance remain key considerations.

Positives

• Achieved a net income of $8.6 million in 2025, a significant turnaround from a $68.6 million net loss in 2024.
• Total revenues increased by $18.8 million to $66.8 million in 2025.
• The pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint and was stopped early for efficacy in May 2025.
• No new safety concerns were identified for tebipenem HBr in the PIVOT-PO trial, with diarrhea and headache being the most reported adverse events.
• GSK submitted the NDA Class 2 resubmission for tebipenem HBr to the FDA in December 2025, and it has been accepted.
• A PDUFA date of June 18, 2026, has been set for tebipenem HBr, indicating a clear regulatory timeline.
• Received a $25.0 million milestone payment in February 2026 for the NDA filing.
• Tebipenem HBr has Qualified Infectious Disease Product (QIDP) and Fast Track designations, potentially leading to priority review and a five-year extension to non-patent exclusivity if approved.
• Cash and cash equivalents of $40.3 million as of December 31, 2025, are projected to fund operations into 2028.
• Securities class action lawsuits and derivative actions against the company and former officers were dismissed or voluntarily dismissed.
• The SEC concluded its investigation into the company and does not intend to recommend an enforcement action against the company.

Negatives

• Ceased development of the SPR206 program in March 2025.
• Ceased development of the SPR720 oral program in November 2025 after the Phase 2a study did not meet its primary endpoint and showed potential dose-limiting safety issues (reversible grade 3 hepatotoxicity at 1,000 mg dose).
• The Pfizer License Agreement for SPR206 was mutually terminated on December 31, 2025, resulting in a liability of up to $5 million to Pfizer from any future sale or partnering of SPR206.
• The company has a history of losses and an accumulated deficit of $451.1 million as of December 31, 2025.
• Grant revenue decreased by $13.4 million in 2025, primarily due to the conclusion of the BARDA-funded Phase 3 trial for tebipenem HBr and termination of the NIAID contract for SPR206.
• Former CEO and CFO settled with the SEC for violations of Section 17(a)(2) of the 1933 Act related to public disclosures from March 31, 2022, to May 3, 2022.
• The company's business and prospects are now substantially dependent on the tebipenem HBr program and the collaboration with GSK, increasing concentration risk.
• An impairment charge of $0.6 million was recorded in Q3 2025 related to real estate leases due to sublease agreements.
• The fourth milestone payment of $1.1 million under Amendment 2 to the GSK License Agreement will not be achieved due to the early stopping of the PIVOT-PO trial.

Risks

• Substantial dependence on the tebipenem HBr program and collaboration with GSK; failure to execute this strategic focus or GSK's failure to advance the program could materially adversely affect the business.
• Ability to realize value from tebipenem HBr depends on obtaining FDA approval, and any imposed requirements could impact commercialization attractiveness.
• Clinical trials may fail to produce favorable results, leading to additional costs, delays, or inability to complete development.
• Serious adverse events or undesirable side effects of product candidates could delay, prevent, or cause withdrawal of regulatory approval, limit commercial potential, or result in negative consequences post-marketing.
• Even if approved, a product candidate may not achieve market acceptance by physicians, patients, hospitals, and third-party payors, leading to smaller market opportunity than estimated.
• Inability to establish sales, marketing, and distribution capabilities or enter into agreements with third parties could hinder commercialization success.
• Substantial competition from other pharmaceutical and biotechnology companies could adversely affect operating results.
• History of losses and expectation of future losses; inability to obtain additional capital could limit operations.
• Failure to achieve milestones triggering payments from collaboration agreements could limit ability to support operations.
• Reliance on third parties for manufacturing clinical supplies increases risk of insufficient quantities or unacceptable costs, delaying, preventing, or impairing development or commercialization efforts.
• Failure to comply with obligations in in-license or acquisition agreements could lead to loss of important rights.
• Use of government funding adds complexity and may impose requirements increasing commercialization and production costs.
• Inability to obtain and maintain sufficient patent protection or broad scope of protection could allow competitors to commercialize similar technologies.
• Failure to enforce registered trademarks or secure registration of pending trademark applications could adversely affect the business.
• Delays in obtaining required regulatory approvals would materially impair revenue generation.
• Price of common stock has been and may continue to be volatile, potentially declining for stockholders.
• Uncertain fate of patents and patent applications in Russia, EAPO, and Ukraine due to geopolitical conflict.
• Inability to protect confidentiality of trade secrets could harm technology value and business.
• Product liability lawsuits could divert resources, incur substantial liabilities, and limit commercialization.
• Failure to comply with environmental, health, and safety laws could result in fines or penalties.
• Internal computer systems or those of contractors may fail or suffer cybersecurity incidents, disrupting development programs and leading to liability.
• Actual or perceived failure to comply with data protection laws could lead to government enforcement actions, private litigation, and adverse publicity.
• Adverse effects from natural disasters and/or health epidemics on business and operations.
• Future success depends on ability to retain key executives and attract/retain qualified personnel.
• Internal restructuring activities could result in business disruptions or harm financial results.
• Conducting business in international markets subjects the company to additional risks if foreign approvals are obtained.
• Unstable global economic and political conditions, including interest rate and inflation volatility, credit market instability, and geopolitical conflicts, could adversely affect business, financial condition, stock price, and ability to raise capital.
• Broad discretion in the use of cash reserves may not be effective.
• Reduced disclosure requirements as a smaller reporting company may make common stock less attractive to investors.
• Increased costs and management time devoted to compliance initiatives and corporate governance as a public company.
• Failure to maintain effective internal controls could affect accurate financial statements and stock price.
• Sales of a substantial number of shares could cause stock price to decline.
• No anticipated cash dividends; stockholders rely on capital appreciation.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult and prevent attempts by stockholders to replace management.
• Securities litigation could divert management attention and harm business.
• Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder the ability to obtain guidance from the FDA and secure timely approval.
• Changes in and uncertainty surrounding U.S. and international trade policies may adversely impact business and operating results.
• Potential for increased litigation against regulatory agencies due to recent Supreme Court decisions.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future, despite achieving net income in 2025. Existing cash and cash equivalents are projected to fund operations into 2028, but additional funding will be required beyond this point to support continued operations and the development of any future product candidates. The company plans to explore equity or debt financings, new collaborations, or grant funding, and may reduce spending if adequate funding is not secured.

Management Comments

• We believe that tebipenem HBr, if approved, could provide a new oral treatment option for adult patients with cUTI, including pyelonephritis, caused by certain microorganisms.
• Following the termination of these earlier stage programs, we remain focused on supporting GSK in the FDA approval process pursuant to our obligations under the GSK License Agreement and advancing other corporate activities, including exploring opportunities to grow our portfolio of clinical-stage product candidates.
• We believe this re-prioritized strategic focus is the best way to optimize our financial and other resources to advance our goal of identifying and developing novel treatments for rare diseases and diseases with high unmet need.
• Our management has broad discretion in the application of our cash reserves and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock.
• Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets.

Industry Context

StockSavvy.ai notes that Spero Therapeutics' strategic shift to focus solely on tebipenem HBr aligns with a broader industry trend of companies streamlining their pipelines to concentrate resources on late-stage assets with clear regulatory pathways, especially in the challenging antibiotic development space. The increasing antibiotic resistance, particularly in Gram-negative bacteria like ESBL-producing Enterobacterales, creates a significant unmet medical need for new oral treatment options for cUTI, positioning tebipenem HBr favorably if approved. The termination of earlier-stage programs (SPR206, SPR720) reflects the high-risk, high-cost nature of early-stage drug development and the necessity for focused investment. The ongoing governmental and regulatory efforts to address antimicrobial resistance (AMR), such as the PASTEUR and DISARM Acts, and the FDA's QIDP designation, indicate a supportive environment for novel antibiotics, potentially offering incentives and extended exclusivity periods.

Comparison to Industry Standards

• Tebipenem HBr, if approved, would be the first oral carbapenem for cUTI in adults, offering a significant advantage over currently available IV-administered carbapenems (e.g., imipenem/cilastatin, meropenem-vaborbactam from CorMedix Inc., relebactam from Merck & Co.).
• The observed activity of tebipenem HBr against a broad spectrum of resistant and MDR Gram-negative bacteria positions it favorably against existing oral therapies like fluoroquinolones (levofloxacin, ciprofloxacin) and trimethoprim/sulfamethoxazole, which face increasing resistance rates (e.g., E. coli resistance to fluoroquinolones in hospital settings was 44.3% in 2024).
• The favorable safety and tolerability profile of tebipenem HBr, supported by years of post-marketing experience in Japan, provides a competitive edge compared to fluoroquinolone products, which have faced strengthened FDA safety warnings.
• The company's financial performance, moving from a significant net loss in 2024 to a net income in 2025, is a positive outlier compared to many clinical-stage biopharmaceutical companies that often report consistent losses until product commercialization.

Management Changes

Corporate Governance

Legal Proceedings

• Two putative securities class action lawsuits (Richard S. Germond v. Spero Therapeutics, Inc. and Kashif Memon v. Spero Therapeutics, Inc.) alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 concerning tebipenem HBr NDA disclosures were dismissed on September 30, 2024, and the case was closed on October 28, 2024.
• A stockholder derivative action (Marti v. Mahadevia, et al.) filed on October 11, 2023, with similar allegations, was voluntarily dismissed on March 31, 2025.
• A second stockholder derivative action (Heil v. Mahadevia, et al.) filed on February 21, 2024, with similar allegations, was voluntarily dismissed on March 20, 2025.
• On January 9, 2025, the company responded to a Wells Notice from the SEC staff regarding a preliminary determination to recommend civil enforcement action against the company, its former CEO (Dr. Mahadevia), and former CFO (Mr. Shukla) related to public disclosures from March 31, 2022, to May 3, 2022.
• On January 16, 2026, the SEC issued a cease-and-desist order against Dr. Mahadevia and Mr. Shukla for violating Section 17(a)(2) of the 1933 Act (untrue statement of material fact or material omission due to negligence). They consented without admitting or denying findings.
• On January 20, 2026, the company received a letter from the SEC stating the investigation into the company was concluded, and the SEC does not intend to recommend an enforcement action against the company at this time.

Related Party Transactions

• GSK License Agreement: GSK is an affiliate. Received $66.0 million upfront payment, $30.0 million development milestone, $95.0 million development milestone (in installments), and $25.0 million NDA filing milestone. GSK also purchased 7,450,000 shares of common stock for $9.0 million.
• Meiji License Agreement: Meiji is a partner. Paid $0.6 million upfront, $1.0 million milestone in 2017, $1.0 million milestone in 2021. Obligated to pay future clinical/regulatory milestones up to $1.0 million and low single-digit royalties. Fully satisfied sublicensee payment obligation of $7.5 million by Q4 2023.
• Pfizer License and Share Purchase Agreements: Pfizer purchased 2,362,348 shares of common stock for $40.0 million. The license agreement was mutually terminated on December 31, 2025.

Stakeholder Impact

• Shareholders: Positive impact from net income, successful Phase 3 trial, and clear regulatory path for tebipenem HBr. Reduced uncertainty from dismissal of lawsuits and conclusion of SEC investigation without action against the company. Potential for future dilution from capital raises. Volatility in stock price remains a risk.
• Employees: Workforce reduction in October 2024 due to restructuring. Retention awards approved for non-executive and executive employees. Management changes with resignations of former CEO and CFO.
• Patients: Potential for a new oral treatment option for cUTI, including pyelonephritis, caused by certain microorganisms, addressing an unmet medical need.
• GSK: Continues as a key partner, responsible for further development and commercialization of tebipenem HBr in its territory.
• Pfizer: Termination of SPR206 license agreement, with a potential future liability of up to $5 million to Pfizer if SPR206 is commercialized by Spero or a successor.
• Meiji: Continues as a partner for tebipenem HBr in certain Asian territories, with potential for future milestone and royalty payments.
• Regulatory Authorities (FDA, SEC): Successful navigation of FDA regulatory process for tebipenem HBr. Resolution of SEC investigation into the company.

Next Steps

• GSK to continue supporting the FDA approval process for tebipenem HBr.
• FDA decision on tebipenem HBr NDA by PDUFA date of June 18, 2026.
• Explore opportunities to grow the portfolio of clinical-stage product candidates.
• Potential commercial launch of tebipenem HBr if approved.
• Potential future equity or debt financings, new collaborations, or grant funding to support operations beyond 2028.
• Management to continue evaluating and potentially reducing spending if adequate additional funding is not secured.
• Negotiated prices for the third cycle of Medicare drugs to become effective on January 1, 2028.
• New EU Pharma Package legislation expected to be adopted by mid-2026, with changes taking effect mid-2028.
• U.S. administration plans to initiate new investigations on major trading partners under Section 301 of the Trade Act of 1974, potentially leading to additional tariffs.

Key Dates

Recommendation

The company has demonstrated a significant turnaround in its financial performance, moving to net income in 2025, largely driven by collaboration revenue and a focused pipeline strategy. The successful Phase 3 trial and clear regulatory path for tebipenem HBr with a PDUFA date in June 2026 are strong positive catalysts. The resolution of the securities litigation and the SEC investigation against the company itself removes significant overhangs. However, the company remains highly dependent on a single product candidate (tebipenem HBr) and its collaboration with GSK, introducing concentration risk. While cash is sufficient into 2028, future capital raises are anticipated, which could lead to dilution. Given the positive developments are largely priced in, and the remaining risks associated with regulatory approval, market acceptance, and future funding, a "hold" recommendation is appropriate for seasoned investors to observe the outcome of the PDUFA date and initial commercialization efforts.

Keywords

Spero Therapeutics, SPRO, Tebipenem HBr, cUTI, Pyelonephritis, Oral Carbapenem, FDA Approval, GSK License Agreement, Biopharmaceutical, Antibiotic Resistance, Clinical Trials, Drug Development, SEC Filing, 10-K, Financial Results, Net Income, Milestone Payments, SPR206, SPR720, Drug Resistance, Corporate Governance, Risk Management, Pharmaceutical Industry